mCRPC patients receiving 225Ac-PSMA-617 therapy in the post-androgen deprivation therapy setting : response to treatment and survival analysis
| dc.contributor.author | Sathekge, Mike Machaba | |
| dc.contributor.author | Bruchertseifer, Frank | |
| dc.contributor.author | Vorster, Mariza | |
| dc.contributor.author | Lawal, Ismaheel Opeyemi | |
| dc.contributor.author | Knoesen, Otto | |
| dc.contributor.author | Mahapane, Johncy | |
| dc.contributor.author | Davis, Cindy | |
| dc.contributor.author | Mdlophane, Amanda | |
| dc.contributor.author | Maes, Alex | |
| dc.contributor.author | Mokoala, Kgomotso M.G. | |
| dc.contributor.author | Mathabe, Kgomotso | |
| dc.contributor.author | Van de Wiele, Christophe | |
| dc.contributor.author | Morgenstern, Alfred | |
| dc.contributor.email | mike.sathekge@up.ac.za | en_US |
| dc.date.accessioned | 2023-07-26T06:50:21Z | |
| dc.date.available | 2023-07-26T06:50:21Z | |
| dc.date.issued | 2022-10 | |
| dc.description.abstract | Please read abstract in the article. | en_US |
| dc.description.department | Nuclear Medicine | en_US |
| dc.description.librarian | hj2023 | en_US |
| dc.description.uri | http://jnm.snmjournals.org | en_US |
| dc.identifier.citation | Sathekge, M., Bruchertseifer, F., Vorster, M., Lawal, I.O., Knoesen, O., Mahapane, J., Davis, C., Mdlophane, A., Maes, A., Mokoala, K., Mathabe, K., Van de Wiele, C. & Morgenstern, A. 2022, 'mCRPC patients receiving 225Ac-PSMA-617 therapy in the post-androgen deprivation therapy setting: response to treatment and survival analysis', Journal of Nuclear Medicine, vol. 63, no. 10, pp. 1496-1502, doi : 10.2967/jnumed.121.263618. | en_US |
| dc.identifier.issn | 0161-5505 (print) | |
| dc.identifier.issn | 2159-662X (online) | |
| dc.identifier.other | 10.2967/jnumed.121.263618 | |
| dc.identifier.uri | http://hdl.handle.net/2263/91638 | |
| dc.language.iso | en | en_US |
| dc.publisher | Society of Nuclear Medicine | en_US |
| dc.rights | © 2022 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY). | en_US |
| dc.subject | 225Ac-PSMA-617 | en_US |
| dc.subject | Prostate specific membrane antigen (PSMA) | en_US |
| dc.subject | Metastatic castration-resistant prostate cancer (mCRPC) | en_US |
| dc.subject | Androgen deprivation treatment (ADT) | en_US |
| dc.subject | Therapy response | en_US |
| dc.subject | PSA response | en_US |
| dc.subject | Prostate carcinoma | en_US |
| dc.subject | Prostate specific antigen (PSA) | en_US |
| dc.subject | SDG-03: Good health and well-being | en_US |
| dc.title | mCRPC patients receiving 225Ac-PSMA-617 therapy in the post-androgen deprivation therapy setting : response to treatment and survival analysis | en_US |
| dc.type | Article | en_US |